Skip to content
ClinCalc Pro
Menu
NSAID (Non-Steroidal Anti-Inflammatory Drug)

Naproxen

Brand names: Naprosyn, Feminax Ultra

Naproxen is a non-steroidal anti-inflammatory drug (NSAID) used for pain, inflammation and gout; in older people it carries heightened gastrointestinal, renal and cardiovascular risks.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits cyclo-oxygenase (COX-1 and COX-2), reducing prostaglandin synthesis and thereby decreasing pain and inflammation.

Prescribing in practice

  • In older patients the gastrointestinal bleeding, renal and cardiovascular risks are increased, so use the lowest effective dose for the shortest time and consider gastroprotection, particularly with other risk factors.
  • Avoid or use caution with anticoagulants, antiplatelets, ACE inhibitors/ARBs and diuretics, and in heart failure, peptic ulcer disease or significant renal impairment.
  • Among non-selective NSAIDs naproxen carries comparatively lower cardiovascular thrombotic risk, which may favour it when an NSAID is needed in a patient with cardiovascular concerns.

Monitoring

Monitor renal function and blood pressure, and remain alert for gastrointestinal symptoms, especially in dehydrated or polypharmacy patients.

Counselling the patient

  • Take with or after food and report black stools, vomiting blood or persistent indigestion.
  • Avoid combining with other anti-inflammatory painkillers, including over-the-counter products.
  • Report ankle swelling, breathlessness or reduced urine output.

Evidence & guidelines

Cardiovascular safety meta-analyses indicate naproxen has a lower thrombotic risk than several other NSAIDs, while MHRA guidance reinforces gastrointestinal and renal caution in older adults.

Reference: NICE CG177 (Gout); NICE NG226 (Osteoarthritis); AGS Beers Criteria 2023; STOPP/START v3; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.